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Improving the Relevance and Consistency of Outcomes Reported in 
Clinical Trials 
 
Abstract 
One of the defining features of patient-centered outcomes research (PCOR) is the 
emphasis on reporting outcomes that are meaningful to patients.  Accelerating 
progress toward this objective could be achieved through increased development 
and uptake of core outcome sets (COS), which are intended to represent a 
standardized minimum set of outcomes that should be measured and reported in 
all clinical trials in a specific condition.  The level of activity around COS has 
increased significantly over recent years, however there are many important 
clinical conditions for which high quality COS have not been developed.     We 
believe that meaningful progress toward the goals behind the significant 
investments in PCOR will depend on sustained attention to the challenges of COS 
development and uptake.      
 
Introduction 
In August 2015, the Patient-Centered Outcomes Research Institute (PCORI) 
announced that they had surpassed the milestone of $1 billion dollars in funding 
for patient–centered outcomes research (PCOR) and comparative effectiveness 
research (CER).  The goal of this investment is to conduct research that will 
improve decision making by patients, clinicians, payers and other stakeholders, 
resulting ultimately in improved public health and reduced health care spending 
[1].  One of the fundamental features distinguishing CER and PCOR from 
traditional clinical research is an emphasis on measuring and reporting outcomes 
that are more meaningful to patients, and that better reflect the decision making 
needs of clinicians, payers and policymakers [2, 3].   Systematic reviews of clinical 
trials have consistently observed problems with the outcomes reported in 
published studies, not only with respect to the relevance of those outcomes, but 
significant variation in which outcomes are reported, the instruments used to 
report them and biases from reporting some, but not all, of the outcomes that 
were collected in the trials.   Because of this, the ability to use clinical trials to 
make reliable comparisons of the effectiveness of therapies is limited.   
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In this paper we provide an overview of the current state of outcomes reporting 
in clinical trials, describe a number of specific initiatives that are working to 
improve outcome reporting in future trials.  The paper focuses most heavily on 
the increasing activity in the development of Core Outcomes Sets (COS), and the 
potential for this work to substantially improve the quality and relevance of 
outcomes measured and reported in clinical research.  Finally, the paper identifies 
a number of gaps in this work and proposes a series of activities necessary to 
accelerate the development and use of more relevant, consistent and patient-
centered outcomes.  We believe that meaningful progress toward the goals 
behind the significant investments in PCOR and CER will depend on sustained 
attention to these challenges and proposed solutions.      
 
Current problems with the outcomes in clinical trials 
A lack of adequate attention to the choice of outcomes in clinical trials has led to 
avoidable waste in both the production and reporting of research.   Currently 
there are three major problems with outcomes reported in clinical trials:  1) 
failure to collect outcomes that are most meaningful to patients, 2) a high degree 
of variability across trials in the outcomes reported, and 3) biased reporting of 
outcomes in published trials.   
 
A number of reports have observed that the outcomes included in clinical 
research have not always been those that patients regard as most important or 
relevant [4].  For example, clinical guidelines issued by the American College of 
Physicians noted that the ability to provide strong recommendations was limited 
by the absence of measures of cognitive function that are commonly used in 
clinical care [5].  Medicare declined to provide reimbursement for cervical 
artificial discs in part because they viewed the outcomes reported in the trials as 
uninformative for key aspects of patient functional abilities.  The primary 
outcome reported for most trials of drugs for psoriasis, which is also the one that 
is required for regulatory approval in the US, is based on a clinician’s judgment of 
the extent of disease, while patients view the distribution of the plaques as most 
meaningful for their quality of life. In their 2012 methodology committee report, 
PCORI provides a standard for patient outcomes that instructs researchers to, 
“measure outcomes that people representing the population of interest notice 
and care about”, to be identified with input from patients and decision makers 
through meetings, surveys or published studies [6].   While this standard should 
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raise awareness of the importance of patient-relevant outcomes, relying on 
individual research teams to select these outcomes independently and informally 
is unlikely to reduce the problems described further below.   
 
The second major problem with outcomes in trials is variability in measurement 
and reporting.  Evidence-based decision making often depends on the ability to 
aggregate results from multiple studies or to make treatment comparisons 
indirectly by looking at results of separate studies.  These efforts depend heavily 
on the degree of consistency in the outcomes that are measured and reported 
across studies.  At present, many studies which explore the effects of the same 
intervention on a specific health condition measure or report different outcomes, 
whether they be patient-reported or clinician-reported. This makes it difficult to 
compare, contrast or combine the findings of these studies when making 
decisions and setting policies, causing problems for people trying to use the 
output from healthcare research. For example, a survey of trials involving people 
with schizophrenia found that 2194 different scales had been used in 10,000 
controlled trials: on average, a new instrument had been introduced for every 
fifth trial [7]. In other research, it has been shown that more than 25,000 
outcomes appeared only once or twice in oncology trials [8].  
 
Difficulties caused by heterogeneity in outcome measurement are well known to 
systematic reviewers [9] and hamper efforts to present guideline developers with 
succinct information on the most important outcomes. For example, Summary of 
Findings (SoF) tables were developed by the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) working group, to provide a 
summary of the evidence for important outcomes, along with the quality of this 
evidence  [10]. They allow for the inclusion of up to seven important reported 
outcomes, providing a way to present the main findings of a review in a simple 
and transparent format. They have been shown to improve readers’ 
understanding and speed of retrieval of the findings of systematic reviews [11] , 
but they will only be effective for decision-making if they include the most 
relevant outcomes for that purpose. However, a recent review found that 
although there has been an increased inclusion of SoF tables in Cochrane Reviews 
since they were introduced in 2008, they were still absent from nearly half of the 
reviews published for the first time in 2013 [12] .  
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The third major problem with outcomes in clinical trials is reporting bias. 
Outcome reporting bias (ORB) occurs as a consequence of the selection for 
publication of a subset of the originally collected outcomes on the basis of the 
results.  This form of bias has been identified as a threat to evidence-based 
medicine because clinical trial outcomes with statistically significant results are 
more likely to be published [13].  The current CONSORT (Consolidating Standards 
of Reporting Trials) statement for reporting trials recommends that completely 
defined primary and secondary outcome measures should be pre-specified and 
any changes to trial outcomes after the trial commenced should be documented 
with reasons [14]. It goes on to recommend that the results for each outcome 
should be reported for each group, along with the estimated effect size and its 
precision.  Despite this guidance, empirical research has shown that statistically 
significant outcomes were more likely to be fully reported compared with non-
significant outcomes (range of odds ratios: 2.2 to 4.7). When comparing trial 
publications with protocols, it was found that 40 to 62% of studies had at least 
one primary outcome that was changed, introduced, or omitted in the time 
period between the production of these documents describing what the 
researchers planned to do and what they eventually did [15]. 
 
Definition and Examples of Core Outcome Sets 
These issues of relevance, inconsistency and outcome reporting bias could be 
improved with the development and application of agreed standardised sets of 
outcomes, known as core outcome sets (COS), to be measured and reported for 
specific areas of health [16]. The outcomes included in a COS could include 
patient-reported outcomes, clinician-reported outcomes, and other patient-
relevant outcomes.  These sets are intended to represent the minimum that 
should be measured and reported in all clinical trials of a specific condition.   
 
The existence or use of a COS does not imply that outcomes in a particular trial 
should be restricted to those in the relevant set. But, the expectation is that the 
core outcomes will always be collected and reported, with researchers including 
additional outcomes of particular relevance or interest to their specific study if 
they wish. The use of COS will make it easier for the results of trials to be 
compared, contrasted and combined, thereby reducing waste in research [17]. 
Their use would greatly reduce heterogeneity between trials because all trials 
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would measure and report the agreed important outcomes, and lead to research 
that is more likely to have measured patient-relevant outcomes. Importantly, 
their use would enhance the value of evidence synthesis by reducing the risk of 
outcome reporting bias and ensuring that all trials contribute usable information 
to a review and meta-analysis.  
 
COS serve an analogous role to having a defined set of quality measures that are 
measured and reported consistently for all public reporting and pay for 
performance programs, such as those developed through the National Quality 
Forum.   These measures have the benefit of being developed through a robust, 
transparent, multi-stakeholder process to ensure that they are relevant, reliable 
and efficient.   They also allow for accurate comparisons across providers, and can 
be aggregated across multiple providers to generate meaningful information on 
trends in outcomes across larger health systems and regions.        
 
An early example of an attempt to standardize outcomes was an initiative by the 
World Health Organization in the 1970s, relating to reporting results of cancer 
treatment trials [18]. More than 30 representatives from groups undertaking 
trials in cancer came together, the result of which was a WHO handbook 
recommending the minimum requirements for data collection in cancer trials.  
This data set included the minimum data that should be made available about the 
patient, the tumor, toxicity and effects of therapy including response, recurrence 
and disease-free survival.  
 
Since then, particularly notable work relating to outcome standardization has 
been undertaken by the OMERACT (Outcome Measures in Rheumatology) 
initiative (www.omeract.org), which has advocated the use of COS, designed 
using consensus techniques, in clinical trials in rheumatology since their first 
conference in 1992 [19]. OMERACT has served a critical role in the development 
and validation of clinical and radiographic outcome measures in rheumatoid 
arthritis, osteoarthritis, psoriatic arthritis, fibromyalgia, and other rheumatic 
diseases.  As an example, the COS recommended for trials of medicinal products 
in the treatment of rheumatoid arthritis included the following seven outcomes: 
tender joints, swollen joints, pain, physician global assessment, patient global 
assessment, physical disability and acute phase reactants.   There are currently 20 
groups working on separate COS within the field of rheumatology, all coordinated 
under the umbrella of OMERACT. 
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The first evaluation of the uptake of a COS related to recommendations made for 
clinical trials of symptom-modifying anti-rheumatic drugs (SMARDS) in the 
treatment of rheumatoid arthritis (RA), ratified in 1994 by the WHO and 
International League of Associations for Rheumatology (ILAR), and also included 
in guidance issued by the FDA and EMA. This study demonstrated that nearly 70% 
of trialists reporting trials in RA are now measuring the COS [20], and 90% of the 
trialists contacted said they would consider using the COS if they were to lead a 
new trial in RA. Clearly, COS have the potential to improve the evidence base for 
health care, but additional work is need to develop strategies to ensure that they 
are disseminated and used by clinical researchers. 
 
Since OMERACT, there have been other examples of similar COS initiatives to 
develop recommendations about the outcomes that should be measured in 
clinical trials. These include the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT, www.immpact.org), whose aim is to 
develop consensus reviews and recommendations for improving the design, 
execution, and interpretation of clinical trials of treatments for pain. Including the 
first IMMPACT meeting in 2002, there have been 17 consensus meetings on 
clinical trials of treatments for acute and chronic pain in adults and children. 
Additional examples are the Harmonizing Outcome Measures for Eczema (HOME, 
www.nottingham.ac.uk/homeforeczema) Initiative and the International 
Dermatology Outcomes Measures (IDEOM, www.dermoutcomes.org), which are 
international groups developing core outcomes to include in trials of the 
treatment of skin conditions. 
 
The COMET Initiative 
Stimulated in part by the success of OMERACT and IMMPACT, as well as the 
increase in awareness of problems with outcomes collected and reported in 
clinical trials, interest and activity in COS has been increasing rapidly over the past 
5 years. The COMET (Core Outcomes Measures for Effectiveness Trials) Initiative 
(www.comet-initiative.org) was established to encourage and support the process 
of developing and implementing COS [21]. It was launched in 2010 with the 
following aims: 1) to raise awareness of current problems with outcomes in 
clinical trials, 2) to encourage COS development and uptake, 3) to promote 
patient and public involvement in COS development, 4) to provide resources to 
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facilitate these aims, 5) to avoid unnecessary duplication of effort, and 6) to 
encourage evidence-based COS development. 
 
COMET aims to collate and stimulate the development, application and 
promotion of COS, by including data on relevant individual studies in a publically 
available internet-based resource. This database includes publications of previous 
COS development projects, as well as planned and ongoing work. A systematic 
review was undertaken in 2013 that provided a first comprehensive search for 
COS in health research [22]. It identified 198 relevant studies that determined 
which outcomes or domains should be measured in clinical trials for a specific 
health condition. The review revealed wide variation in the methods used to 
develop COS and work is needed to assess the implications of these different 
methods for both minimizing bias and maximizing efficiency in the development 
of COS, and for ensuring uptake. As an example, although benefits have been 
shown for involving patients in trial design, only 16% of the published COS 
reported that there was input from patients in their development [23].  The 
review highlighted the need for methodological guidance, including how to 
engage key stakeholder groups, particularly members of the public, in the 
development and implementation of COS.  
 
This review was updated to the end of 2014, and a further 29 new COS studies 
were identified [24].  There has been a general increase in the number of COS 
over the years, with a consistently higher number of COS published annually in 
recent years than in most years before 2010 (Figure 1). The studies identified 
have been added to the COMET database in order to provide an up-to-date, 
comprehensive database of COS. In addition, to reduce unnecessary duplication 
of effort, ongoing COS studies are also registered in the database. Figure 2 shows 
the number of COS developed, or in development, according to health category. 
Taken together, this work has identified many health areas where a COS has been 
developed and highlighted important gaps.  For example, there has been 
substantial work on COS for rheumatology and neurology, while mental health 
conditions have not received significant attention. 
 
As awareness of the need for COS continues to grow and knowledge of the 
COMET Initiative increases, this is reflected in the website and database usage 
figures [17, 25]. More than 16,500 visits were made to the website in 2014 (36% 
increase over 2013) and 9780 new visitors (43% increase). By December 2014, a 
Page 7 of 54
https://mc04.manuscriptcentral.com/fm-cer
Journal of Comparative Effectiveness Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Tunis et al., page 8 
 
total of 6588 searches had been completed of the COMET database, with 2383 in 
that year alone (11% increase). An online survey in May-June 2015 was answered 
by 206 (52%) of the 396 visitors to the website, and revealed that the most 
common reasons for searches were ‘I am thinking about developing a core 
outcome set’ and ‘I am planning a clinical trial’.  
 
 
Methods for Developing COS 
 
While standardized methods for the development of COS have not yet been 
widely adopted, a fairly well-defined set of issues to consider are increasingly 
being addressed [16]. A detailed handbook with step-by-step instructions on the 
COS development process has been developed by OMERACT, and is regularly 
updated with insights generated through ongoing COS work [26].  At a high level, 
the first stage in the development of a COS is most frequently a decision on what 
outcomes or outcome domains to measure, followed by agreement on how those 
outcomes should be defined and measured in order to provide the necessary 
data, adopting the outcome specification model previously described [27]. COS 
may include both patient-reported outcomes (PROs) and clinician-reported 
outcomes (ClinROs). Several existing initiatives, described in the next section, are 
relevant to the process of determining how an outcome should be defined and 
measured; and a practical guideline has recently been developed [28].  
 
As noted above, COS have been developed using a variety of methods [22, 24]. 
These include the use of a literature/systematic review as an early step, which 
rose from 33% (66/198) of the studies in the original review to 72% (21/29) in the 
update. A variety of methods have been used to assess and develop consensus, 
with the Delphi technique used for 15% (29/198) of the COS in the original review 
and 31% (9/29) in the update. 
The stakeholder groups regarded as key to developing a COS varies between 
health areas. Clinical experts have been involved in all studies, but there has been 
a recent shift towards greater involvement of patient and public representatives. 
This increased, where reported, from 18% (31/174) in the original review, to 59% 
(13/22) in the update, and 89% (66/74) among the ongoing studies that are 
registered in the COMET database.  
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Involving the public in research can bring challenges and, in response to this need, 
COMET has established the PoPPIE (People and Patient Participation, Involvement 
and Engagement) Working Group to develop resources, including the 
development of plain language summaries in partnership with patients 
(www.comet-initiative.org/resources/PlainLanguageSummary), and pursue a 
research agenda. Research is needed on how to: involve patients as research 
partners in design of COS studies; identify and meet information needs of patients 
as both research partners and participants; identify appropriate methods for 
eliciting consensus among patient groups; generate appropriate questions for 
patients taking part in a COS study; access and engage patients in COS studies; 
ensure hard to reach communities are involved; bring different stakeholder 
groups’ views together; and evaluate the stakeholder experience of taking part.  
 
Other initiatives involving standardized outcomes 
A number of programs and initiatives in the US and elsewhere overlap to some 
degree with the expanding work on COS, and present opportunities for 
coordination and collaboration, as well as the need to avoid duplication of effort.   
 
PROMIS (www.nihpromis.org) is an NIH initiative which provides a system of 
measures of patient-reported health status for physical, mental, and social health 
and can be used in studies across a range of medical conditions.  A primary 
objective of PROMIS is to assemble a set of questions to assess the most common 
dimensions of patient–reported outcomes for a wide range of chronic diseases. 
These include items to measure pain, fatigue, psychological distress, physical 
function, and overall health. The PROMIS database of measures focusses on 
patient-reported outcomes, while COS generally include both patient-reported 
and clinician-reported outcomes, as well as other outcomes such as laboratory 
results, etc. PROMIS focusses on 'how' to measure 'items' that are patient-
reported, providing an item question bank. The 'how' is typically the second stage 
of a COS, with the 'what' coming first.   In addition, PROMIS does not seek to 
develop agreement around a defined set of minimum outcomes to measure and 
report in a standard fashion across studies, and, by itself therefore, would not 
address the fundamental problems of relevance, consistency or reporting bias 
discussed above. 
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The National Institutes of Health (NIH) has also taken steps to encourage the use 
of common data elements (CDEs), including outcomes, in NIH supported research 
projects or registries. The NIH provide a resource portal (www.nlm.nih.gov/cde) 
that includes databases and repositories of data elements and case report forms 
that might help investigators in identifying and selecting data elements for use in 
their projects.  The NIH CDE program is most relevant to researchers once they 
have determined ‘what’ to measure, offering resources on ‘how’ to measure both 
particular outcomes and other relevant data items. 
The International Consortium for Health Outcomes Measurement (ICHOM, 
www.ichom.org) organizes global teams of physician leaders, outcomes 
researchers and patient advocates to define core sets of outcomes for use for 
specific health conditions to assess the quality of clinical practice. This initiative 
was established with the aim of providing a structured process to achieve 
consensus data collected standards to be used outside the context of clinical 
trials, and hopes to publish 50 standard sets by 2017. A list of completed sets, in 
progress and conditions under consideration is available at 
www.ichom.org/medical-conditions.  
ICHOM is focusing on the development of core data sets to evaluate the quality 
and efficiency of clinical care, rather than for use in clinical trials.  The methods 
used by ICHOM differ substantially from those used in the development of COS 
for clinical trials (even taking account of the variability in methods used for the 
latter), as discussed in more detail below.  It is unclear whether the outcomes sets 
developed by ICHOM for clinical care would also be useful for clinical research, 
although there would be value in developing standards that could be used for 
both purposes, making it possible to re-use data collected for either reason.   
As an example, ICHOM recently published their consensus measures for patients 
treated for prostate cancer [29], but provided limited detail on the specific 
methods used to reach agreement on the recommended measures. It would be 
valuable to have more information on those methods, such as how the number of 
patients and other stakeholders was decided; how patients were identified, 
selected and involved in the process; how final decisions of the inclusion of an 
outcome were made [30].  In addition, it is important to know how the measuring 
tools were selected. For instance, the ICHOM standards require a record of the 
date of recurrence of an abnormal PSA , but the variety of definitions of PSA 
recurrence (either within a treatment or across treatments) could render 
comparisons difficult and problematic, particularly for clinical trials [30].  
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The FDA Clinical Outcome Assessments (COA) Staff aim to encourage the 
development and application of patient-focused endpoint measures in medical 
product development to highlight clinical benefit in labeling. They engage with 
stakeholders to improve clinical outcome measurement standards and policy 
development, by providing guidance on COA development, validation, and 
interpretation of clinical benefit endpoints in clinical trials. Unmet medical needs 
are addressed through the Clinical Outcomes Assessment Qualification Program. 
COA qualification is dependent on appraisal of the evidence to support the 
conclusion that the COA is a well-defined and reliable assessment of a particular 
concept of interest for application in studies used to support drug marketing 
authorization.   The European Medicines Agency (EMA) is working along similar 
lines to increase the use of well validated patient-relevant outcomes in their 
regulatory process.   
The main focus of the FDA and EMA work is understandably on the endpoints to 
be used in product approvals and labelling, and has not been concerned to date 
with the assessment of effectiveness involving outcomes that may be useful for 
non-regulatory decisions by patients, clinicians, payers and others.   From a 
regulatory perspective, the emphasis is on outcomes that are customized to 
specific products and indications, rather than aiming for greater standardization 
of outcomes across products and studies.  Furthermore, the degree of focus on 
patient-relevant outcomes, and inclusion of patients and the public has been 
limited to date.   This may be changing as a result of greater attention to “patient-
focused drug development”, and may ultimately lead the FDA to greater 
consideration of outcomes that are relevant to and informed by patients [31].  For 
example work on Core Symptom Measures for cancer trials has been promoted in 
prostate, head and neck and ovarian cancers [32]. Whilst the processes to elicit 
expert opinion has included some patient involvement, it is quite limited [33] and 
greater emphasis of wider patient involvement in the process of selecting core 
outcomes is recommended.  
In considering the measurement instruments to use, several may exist for any 
given outcome, usually with varying psychometric properties (i.e. reliability and 
validity). Systematic reviews of measurement instruments provide one way to 
select a measurement instrument for an outcome within a COS. The COSMIN 
(COnsensus-based Standards for the selection of health Measurement 
INstruments) initiative collates systematic reviews of studies of measurement 
properties of existing measurement instruments that intend to measure (aspects 
Page 11 of 54
https://mc04.manuscriptcentral.com/fm-cer
Journal of Comparative Effectiveness Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Tunis et al., page 12 
 
of) health status or (health-related) quality of life. An overview of these reviews 
and guidelines for performing such reviews can be found at 
www.cosmin.nl/systematic-reviews-of-measurement-properties-_5_0.html.  
 
Key challenges and moving forward 
While it is encouraging that the level of activity around COS has been increasing, 
substantial work remains to be done, and there are a number of key challenges 
that must be addressed to accelerate progress.   To inform how best to move 
forward, the Center for Medical Technology Policy and the COMET initiative 
hosted a one day COS workshop in April 2014, supported with funding from 
PCORI, The European Union and the UK Medical Research Council.   The meeting 
opened with presentations by ten North American experts currently developing 
COS for use in clinical trials, patient-centered outcomes research (PCOR), 
systematic reviews, quality improvement and other contexts.  Each presentation 
was followed by discussion and f edback from representatives of federal agencies 
and national organizations with an interest in condition-specific, standardized 
health outcomes, including most of those described above.  The discussions 
underscored the need to expand capacity to develop high quality COS, and 
identified several issues requiring attention to promote further progress.   These 
challenges and potential strategies to address them are summarized below.  
 
Better understanding of the gaps in COS 
The number and quality of COS remains limited, despite the recent increase in 
activity in this field.   While a systematic review of gaps has not yet been done, an 
initial attempt has been made to map the content of the COS database to the 
most prevalent acute and chronic conditions.   For example, no COS have been 
published regarding trials of drug therapy for type 2 diabetes or interventions for 
the management of chronic wounds.   And for many other conditions, the 
available COS have used informal consensus methods rather than structured 
approaches, which might undermine their acceptability for a wide range of 
decision makers.  An initial informal review of conditions identified by the WHO as 
being responsible for the highest global burden of disease [34] has identified key 
gaps. A more systematic assessment of these gaps is now underway.  Again, even 
if existing COS have been identified, further work is needed to determine whether 
they are of adequate quality to broadly promote. 
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An important next step would be to conduct a systematic assessment to identify 
those high prevalence, high burden conditions for which high quality COS do not 
yet exist.  This could be done by using work that has already been done to identify 
and rank burden of illness globally or nationally.   For example, in the US, the 
Agency for Health Care Research and Quality has developed priorities for 
comparative effectiveness research, as have the Institute of Medicine and PCORI.   
Having identified the priority conditions, published COS in those clinical domains 
could be found relatively simply through the COMET database.  Finally, these COS 
would be need to be assessed for quality, of both their methods and reporting.   
As noted below, work is underway to develop quality assessment and reporting 
tools for COS, but the initial quality screening could look for a few basic indicators 
of quality, such as the inclusion of patients or consumers in the development 
process.  
 
Expanded capacity to produce COS 
As priority areas for COS are identified, mechanisms need to be in place to 
support their development and implementation. This will require research to 
identify best practices for COS development and the production of a reporting 
guideline to facilitate clear reporting of the COS and the processes used to 
develop it (see below). This would likely be accelerated by an increased interest in 
research funding agencies to support the development of high priority COS, and 
of the methods and tools necessary to support groups involved in this work.   The 
nature of this work requires multi-stakeholder collaboration, ideally at the 
national or international level.  Ideally, many of these initiatives would include 
leadership from the patient advocacy organizations relevant to each topic.  In this 
way, the benefits of COS for reducing waste in research will not arise from 
wasteful practices in their development [35] . 
As part of its effort to support COS developers, the COMET database includes 
previous work that might help the development of new COS, alongside the 
reports of COS themselves. For example, an initial step in COS development is 
usually a review of outcomes measured in previous clinical trials and work to 
identify outcomes felt to be important by patients. With this in mind, the 
database includes more than 120 reviews of outcomes measured in trials and 52 
studies of patients’ perspectives on outcomes to be measured in their condition. 
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Improving the quality of COS 
The afore-mentioned systematic review and its update revealed wide variation in 
the methods used to develop COS, with no clear consensus on best practice ([22]; 
Gorst et al, in preparation). Although key issues to consider when developing a 
COS have been described [16], there is little or no guidance on how to choose and 
involve stakeholders, develop consensus, achieve geographical representation, or 
undertake many other aspects of the process.     
One of the urgent areas of need is to expand engagement of patients and the 
public in the development of COS.   As noted above, a significant minority of 
published reported any patient or public involvement in the process.  There is 
anecdotal evidence to suggest that this has started to shift, and the forthcoming 
updated systematic review of COS will provide more recent empirical data.  Given 
the rapidly increasing recognition of the need to develop, validate and report 
outcomes that are meaningful to patients, it is a critical priority to fund methods 
research to develop and validate formal qualitative methods to effectively engage 
patients and the public in this process.    The absence of empirically-based best 
practices should not prevent the development of initial consensus around key 
principles and techniques.   Once documented and standardized to some extent, 
it will be possible to do empirical work to evaluate the effectiveness of alternative 
approaches.  
When best practices have been developed, it will also be possible and useful to 
develop a quality assessment tool.  Although nearly 230 published COS studies 
have already been identified, the lack of an assessment tool means that there has 
been no formal quality assessment of these. Defining the quality of a COS is not 
straightforward. Ultimately, a “good” COS would be one that leads to improved 
health outcomes but this might be far down-stream of the development process 
and difficult to measure. It is also unlikely to be a feature of any report describing 
the development of a COS. Instead, a tool is needed to assess how the COS 
developers minimized biases which would otherwise undermine the ability of the 
COS to have a positive impact on patient care and outcomes. This would be 
analogous to the Cochrane Risk of Bias tool for assessing the studies to include in 
systematic reviews [36]. 
Along with best practice guidance and metrics to assess the quality of COS, it will 
be valuable to develop a standardized reporting tool for publications and reports 
of COS.  Although a preliminary checklist was proposed for the reporting of Delphi 
surveys used in the development of COS [37], this is not sufficient to address the 
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wider aspects of COS studies. COS studies are still not well reported in terms of 
the scope and methods used in the development of the COS. Information that 
might help users to decide whether to adopt a COS or develop a new one is often 
lacking. To try to redress this, work is underway to develop a COS reporting 
guideline, using an international consensus process [38]. The initial areas under 
consideration include the rationale for and scope of the COS, methods of 
development, stakeholder involvement, sources of information, consensus 
process, limitations, and plans for implementation and updating.  
 
Increasing uptake of high quality COS 
Where high quality COS exist or are developed, they will need to be widely 
accepted and implemented by the majority of researchers if their benefits for 
health are to be realized.   Publication and broad dissemination of the COS is a 
basic requirement, and the simplified access to relevant reports and papers is 
now possible as a result of the work of COMET.  Stronger incentives are likely to 
be necessary for high levels of uptake, for example, the recognition or 
endorsement of COS by research funding organizations, journal editors, clinical 
guideline developers and payer/HTA organizations.   Researchers should be 
considerably more likely to give serious consideration to COS when that decision 
has the potential to impact the funding of their research, publication of their 
results, of have an influence over clinical policy or reimbursement.   
With respect to research funders, the National Institute for Health Research 
(NIHR) in the UK provides the following text in their guidance notes for applicants: 
“Where established Core Outcomes exist they should be included amongst the list 
of outcomes unless there is good reason to do otherwise. Please see The COMET 
Initiative website at www.comet-initiative.org to identify whether Core Outcomes 
have been established”.  There are not yet examples of US funders making explicit 
reference to COS, but the NIH, AHRQ, PCORI and others may wish to consider 
under what circumstances it would be reasonable to do so.  
Some journal editors have begun to encourage consideration of COS by 
researchers.  The SPIRIT guidance for reporting protocols of clinical trials [39] 
recommends “Where possible, the development and adoption of a common set 
of key trial outcomes within a specialty can help to deter selective reporting of 
outcomes and to facilitate comparisons and pooling of results across trials in a 
meta-analysis. The COMET (Core Outcome Measures in Effectiveness Trials) 
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Initiative aims to facilitate the development and application of such standardized 
sets of core outcomes for clinical trials of specific conditions (www.comet-
initiative.org). Trial investigators are encouraged to ascertain whether there is a 
core outcome set relevant to their trial and, if so, to include those outcomes in 
their trial. Existence of a common set of outcomes does not preclude inclusion of 
additional relevant outcomes for a given trial”. Finally, in obstetrics and 
gynecology, the CROWN (Core Outcomes in Women’s Health) Initiative 
(www.crowninitiative.org) is a consortium of more than 70 journal editors that 
will “strongly encourage the reporting of results for core outcome sets. Facilitate 
embedding of core outcome sets in research practice, working closely with 
researchers, reviewers, funders and guideline makers”. 
There is considerable potential for increasing uptake of COS through the 
mechanism of recognition by clinical guideline developers, HTA organizations and 
payers – as these groups all carry substantial influence through their direct 
influence on the evidence-based reimbursement of products and services.  The 
manual for guideline development by the National Institute for Health and Care 
Excellence (NICE) recommends the COMET database as a source of information to 
be considered (NICE, 2012).   The Green Park Collaborative (GPC) in the US 
(www.cmtpnet.org/featured-projects/green-park-collaborative) develops 
recommendations for research in specific therapeutic areas, through a multi-
stakeholder collaborative process that includes payers, guideline developers, HTA 
organizations, as well as patients, clinicians and other key stakeholders.   A 
number of GPC projects have attempted to increase the measurement and 
reporting of patient-relevant outcomes [40].  Efforts are also underway to 
leverage the broad range of decision making authority represented by the 
membership of this collaborative to promote the uptake of high quality COS.    
Ultimately, it is likely that explicit recognition or formal endorsement of COS will 
be necessary to ensure the level of consistent use that will achieve the original 
objectives of this work. 
 
Conclusions 
If comparative effectiveness research is to have an impact on practice and, 
thereby, the health of patients and the public, it needs to ensure that the 
outcomes that matter most to the people making decisions and choices are 
measured and reported. Core outcome sets can facilitate this, especially when 
their development and implementation is integrated with other key initiatives to 
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improve research and practice. There are several challenges to overcome. Work is 
already underway to meet some of these, including a database of all identified 
COS, research to identify best practices and the development of a reporting 
guideline. However, much remains to be done. Health areas in particular need of 
COS have to be identified, the development of high quality COS to meet this need 
has to be encouraged and supported, and these COS have to be implemented in 
research and practice. 
In addition to standardized outcomes in clinical trials, consistent reporting of 
outcomes is also important for studies of the onset, course and consequences of 
disease. To this end, clinical cohorts, registries and observational databases have 
been established; and routinely collected data from within electronic medical 
record (EMR) systems is likely to become increasingly available in the future to 
support research. The EMR provides real-world clinical information and is a 
sustainable source of data. The overlap between data from research databases 
and from EMR systems for clinical care could be valuable. Therefore, to achieve 
the full potential of such an approach, it is vital that similar attention is paid to the 
choice and definition of outcomes that should be collected within such systems.  
It has also been proposed that prospective registries of clinical trials should place 
increased emphasis on COS [41]. For example, registries could encourage 
researchers to note their use of a COS when they register their trial, perhaps with 
a prompt for them to consider using a COS and a simple way for them to specific 
the outcomes by a link through to the original COS.   
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Figure 1 Year of first publication of each COS study (n=227) 
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Figure 2 Number of COS developed in each disease category (n=305)  
 
*Studies we are aware have been published since December 2014 
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Improving the Relevance and Consistency of Outcomes 
Reported in Clinical Trials Comparative Effectiveness 
Research 
 
Abstract 
Policy makers have clearly indicated--through heavy investment in the Patient 
Centered Outcomes Research Institute (PCORI)--that reporting outcomes which 
are meaningful to patients is crucial for improvement in health care delivery and 
cost reduction.  Better interpretation and generalizability of clinical research 
results that incorporate PCOR can be achieved by accelerating the development 
and uptake of Core Outcome Sets (COS).One of the defining features of patient-
centered outcomes research (PCOR) is the emphasis on reporting outcomes that 
are meaningful to patients, and that reflect the decision making needs of 
clinicians, payers and policymakers.  Accelerating progress toward this objective 
could be achieved through increased development and uptake of core outcomes 
sets (COS), which are intended to represent COS provide a standardized minimum 
set of the outcomes that should be measured and reported in all clinical trials of a 
specific condition.  The level of activity around COS has increased significantly 
over the past decade, with substantial progress in several clinical domains.  
However, there are many important clinical conditions for which high quality COS 
have not been developed and limited capacity and resources to develop them.   
Methods for developing COS are still highly variable, particularly with respect to 
engaging patients and the public.   Systematic approaches to promote uptake are 
also needed.  It will also be important to ensure coordination and collaboration 
across groups that are working to improve outcomes reporting for purposes other 
than PCOR.    We believe that meaningful progress toward the goals behind the 
significant investments in PCOR and CER will depend on sustained attention to 
these challenges and proposed solutions.     We believe that meaningful progress 
toward the goals behind the significant investments in PCOR and CER will depend 
a serious effort to address these issues.   
 
 
Introduction 
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In August 2015, the Patient-Centered Outcomes Research Institute (PCORI) 
announced that they had surpassed the milestone of $1 billion dollars in funding 
for patient–centered outcomes research (PCOR) and comparative effectiveness 
research (CER).  The goal of this investment is to conduct research that will 
improve decision making by patients, clinicians, payers and other stakeholders, 
resulting ultimately in improved public health outcomes and reduced health care 
spending [1].  One of the fundamental features distinguishing CER and PCOR from 
traditional clinical research is an emphasis on measuring and reporting outcomes 
that are more meaningful to patients, and that better reflect the decision making 
needs of clinicians, payers and policymakers [2, 3].   Systematic reviews of clinical 
research trials have consistently observed serious problems with the outcomes 
reported in published studies, not only with respect to the relevance of those 
outcomes, but significant variation in which outcomes are reported, the 
instruments used to report them and biases from reporting some, but not all, of 
the outcomes that were collected in the trials.   Because of this, the ability to use 
clinical studiestrials to make reliable comparisons of the effectiveness of 
therapies is limited, providing suboptimal returns on the substantial investments 
made to support these studies.   
In this paper we provide an overview of the current state of outcomes reporting 
in clinical researchtrials, and identifydescribing a number of specific initiatives 
that are working to improve outcome reporting in future studiestrials.  The paper 
focuses most heavily on the increasing activity in the development of Core 
Outcomes Sets (COS), and the potential for this work to substantially improve the 
quality and relevance of outcomes measured and reported in clinical research.  
Finally, the paper identifies a number of gaps in this work and proposes a series of 
activities necessary to accelerate the development and use of more relevant, 
consistent and patient-centered outcomes.  The activities currently underway are 
not adequate in scope or magnitude to address the critical problems with 
research outcomes described in this paper.  We believe that rapid and meaningful 
progress toward the goals behind the significant investments in PCOR and CER will 
depend on depend on sustained attention to these challenges and proposed 
solutions. implementation of an intensive, coordinated and sustained effort to 
develop, measure and report relevant, reliable, patient-centered and 
standardized health outcomes.      
 
Current problems with the outcomes in clinical trials 
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A lack of adequate attention to the choice of outcomes in clinical trials has led to 
avoidable waste in both the production and reporting of research.   Currently 
there are fivethree major problems with outcomes reported in clinical trials:  1) 
failure to collect outcomes that are most meaningful to patients, 2) a high degree 
of variability across trials in the outcomes reported, and 3) biased reporting of 
outcomes in published trialsvariation in outcome measurement instruments used, 
4) lack of information on the measurement properties of the instruments, and 5) 
biased reporting of outcomes in published trials.   
 
A number of reports have observed that the outcomes included in clinical 
research have not always been those that patients regard as most important or 
relevant [4].  For example, clinical guidelines issued by the American College of 
Physicians noted that the ability to provide strong recommendations was limited 
by the absence of measures of cognitive function that are commonly used in 
clinical care [5].  Medicare declined to provide reimbursement for cervical 
artificial discs in part because they viewed the outcomes reported in the trials as 
uninformative for key aspects of patient functional abilities [6].  The primary 
outcome reported for most trials of drugs for psoriasis, which is also the one that 
is required for regulatory approval in the US, is based on a clinician’s judgment of 
the extent of disease, while payers, clinicians and patients view the distribution of 
the plaques and impact on functioning as most meaningful for their quality of life 
[7]. In their 2012 methodology committee report, PCORI provides a standard for 
patient outcomes that instructs researchers to, “measure outcomes that people 
representing the population of interest notice and care about”, to be identified 
with input from patients and decision makers through meetings, surveys or 
published studies [8].   While this standard should raise awareness of the 
importance of patient-relevant outcomes, relying on individual research teams to 
select these outcomes independently and informally is unlikely to reduce the 
problems described further below.   
 
The second major problem with outcomes in trials is variability in measurement 
and reporting.  Evidence-based decision making often depends on the ability to 
aggregate results from multiple studies or to make treatment comparisons 
indirectly by looking at results of separate studies.  These efforts depend heavily 
on the degree of consistency in the outcomes that are measured and reported 
across studies.  At present, many studies which explore the effects of the same 
intervention on a specific health condition measure or report different outcomes, 
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whether they be patient-reported or clinician-reported. This makes it difficult to 
compare, contrast or combine the findings of these studies when making 
decisions and setting policies, causing problems for people trying to use the 
output from healthcare research. For example, a survey of trials involving people 
with schizophrenia found that 2194 different scales had been used in 10,000 
controlled trials: on average, a new instrument had been introduced for every 
fifth trial [9]. In other research, it has been shown that more than 25,000 
outcomes appeared only once or twice in oncology trials [10].  
 
Consensus is also needed on how selected outcomes should be defined and 
measured. There is often a variety of instruments being used for measuring the 
same outcome, with great variability in how outcomes are measured, scored and 
reported. Incomparable scores from different instruments further hampers 
evidence synthesis in systematic reviews. There is also great variability in the 
quality (reliability and validity) of measures used and there is a need for guidance 
on how to select the best instrument for a given outcome. 
 
Difficulties caused by heterogeneity in outcome measurement are well known to 
systematic reviewers [11] and hamper efforts to present guideline developers 
with succinct information on the most important outcomes. For example, 
Summary of Findings (SoF) tables were developed by the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) working 
group, to provide a summary of the evidence for important outcomes, along with 
the quality of this evidence  [12]. They allow for the inclusion of up to seven 
important reported outcomes, providing a way to present the main findings of a 
review in a simple and transparent format. They have been shown to improve 
readers’ understanding and speed of retrieval of the findings of systematic 
reviews [13] , but they will only be effective for decision-making if they include 
the most relevant outcomes for that purpose. However, a recent review found 
that although there has been an increased inclusion of SoF tables in Cochrane 
Reviews since they were introduced in 2008, they were still absent from nearly 
half of the reviews published for the first time in 2013 [14] .  
 
The fifththird major problem with outcomes in clinical trials is reporting bias. 
Outcome reporting bias (ORB) occurs as a consequence of the selection for 
publication of a subset of the originally collected outcomes on the basis of the 
results.  This form of bias has been identified as a threat to evidence-based 
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medicine because clinical trial outcomes with statistically significant results are 
more likely to be published [15].  The current CONSORT (Consolidating Standards 
of Reporting Trials) statement for reporting trials recommends that completely 
defined primary and secondary outcome measures should be pre-specified and 
any changes to trial outcomes after the trial commenced should be documented 
with reasons [16]. It goes on to recommend that the results for each outcome 
should be reported for each group, along with the estimated effect size and its 
precision.  Despite this guidance, empirical research has shown that statistically 
significant outcomes were more likely to be fully reported compared with non-
significant outcomes (range of odds ratios: 2.2 to 4.7). When comparing trial 
publications with protocols, it was found that 40 to 62% of studies had at least 
one primary outcome that was changed, introduced, or omitted in the time 
period between the production of these documents describing what the 
researchers planned to do and what they eventually did [17].  While it is not 
uncommon for investigators to modify study protocols, this high frequency of 
changes to primary outcomes highlights the potential for significant outcome 
reporting bias, and the potential benefit of widely agreed, standardized 
outcomes.   Previous work, examining two separate cohorts of Cochrane 
systematic reviews, has shown that 55% (157/283) of reviews in the first cohort 
could not include data for the review on the primary outcome from all eligible 
studies [13], and 86% (79/92) of the second cohort could not include full data 
from the main harm outcome of interest for all studies [18]. [ ]. 
 
 
Definition and Examples of Core Outcome Sets 
These issues of relevance, inconsistency and outcome reporting bias could be 
improved with the development and application of agreed 
standardisedstandardized sets of outcomes, known as core outcome sets (COS), 
to be measured and reported for specific areas of health [19]. The outcomes 
included in a COS could include patient-reported outcomes, clinician-reported 
outcomes, and other patient-relevant outcomes.  These sets are intended to 
represent the minimum that should be measured and reported in all clinical trials 
of a specific condition.   
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The existence or use of a COS does not imply that outcomes in a particular trial 
should be restricted to those in the relevant set. But, the expectation is that the 
core outcomes will always be collected and reported, with researchers including 
additional outcomes of particular relevance or interest to their specific study if 
they wish. The use of COS will make it easier for the results of trials to be 
compared, contrasted and combined, thereby reducing waste in research [20]. 
Their use would greatly reduce heterogeneity between trials because all trials 
would measure and report the agreed important outcomes, and lead to research 
that is more likely to have measured patient-relevant outcomes. Importantly, 
their use would enhance the value of evidence synthesis by reducing the risk of 
outcome reporting bias and ensuring that all trials contribute usable information 
to a review and meta-analysis.  
 
COS serve an analogous role to having a defined set of quality measures that are 
measured and reported consistently for all public reporting and pay for 
performance programs, such as those developed through the National Quality 
Forum.   These measures sets have the benefit of being endorseddeveloped 
through a robust, transparent, multi-stakeholder process to ensure that they are 
relevant, reliable and efficient.   They also allow for accurate comparisons across 
providers, and can be aggregated across multiple providers to generate 
meaningful information on trends in process and outcomes, including patient 
reported outcomes, across larger health systems and regions.        
 
An early example of an attempt to standardize outcomes was an initiative by the 
World Health Organization in the 1970s, relating to reporting results of cancer 
treatment trials [21]. More than 30 representatives from groups undertaking 
trials in cancer came together, the result of which was a WHO handbook 
recommending the minimum requirements for data collection in cancer trials.  
This data set included the minimum data that should be made available about the 
patient, the tumor, toxicity and effects of therapy including response, recurrence 
and disease-free survival.  
 
Since then, particularly notable work relating to outcome standardization has 
been undertaken by the OMERACT (Outcome Measures in Rheumatology) 
initiative (www.omeract.org), which has advocated the use of COS, designed 
using consensus techniques, in clinical trials in rheumatology since their first 
conference in 1992 [22]. OMERACT has served a critical role in the development 
Page 27 of 54
https://mc04.manuscriptcentral.com/fm-cer
Journal of Comparative Effectiveness Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
Tunis et al., page 7 
 
and validation of clinical and radiographic outcome measures in rheumatoid 
arthritis, osteoarthritis, psoriatic arthritis, fibromyalgia, and other rheumatic 
diseases.  As an example, the COS recommended for trials of medicinal products 
in the treatment of rheumatoid arthritis included the following seven outcomes: 
tender joints, swollen joints, pain, physician global assessment, patient global 
assessment, physical disability and acute phase reactants.   There are currently 20 
groups working on separate COS within the field of rheumatology, all coordinated 
under the umbrella of OMERACT. 
 
The first evaluation of the uptake of a COS related to recommendations made for 
clinical trials of symptom-modifying anti-rheumatic drugs (SMARDS) in the 
treatment of rheumatoid arthritis (RA), ratified in 1994 by the WHO and 
International League of Associations for Rheumatology (ILAR), and also included 
in guidance issued by the FDA and EMA. This study demonstrated that nearly 70% 
of trialists reporting trials in RA are now measuring the COS [23], and 90% of the 
trialists contacted said they would consider using the COS if they were to lead a 
new trial in RA. Clearly, COS have the potential to improve the evidence base for 
health care, but additional work is need to develop strategies to ensure that they 
are disseminated and used by clinical researchers. 
 
Since OMERACT, there have been other examples of similar COS initiatives to 
develop recommendations about the outcomes that should be measured in 
clinical trials. These include the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT, www.immpact.org), whose aim is to 
develop consensus reviews and recommendations for improving the design, 
execution, and interpretation of clinical trials of treatments for pain. Including the 
first IMMPACT meeting in 2002, there have been 17 consensus meetings on 
clinical trials of treatments for acute and chronic pain in adults and children. 
Additional examples are the Harmonizing Outcome Measures for Eczema (HOME, 
www.nottingham.ac.uk/homeforeczema) Initiative and the International 
Dermatology Outcomes Measures (IDEOM, www.dermoutcomes.org), which are 
international groups developing core outcomes to include in trials of the 
treatment of skin conditions. 
 
The COMET Initiative 
Stimulated in part by the success of OMERACT and IMMPACT, as well as the 
increase in awareness of problems with outcomes collected and reported in 
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clinical trials, interest and activity in COS has been increasing rapidly over the past 
5 years. The COMET (Core Outcomes Measures for Effectiveness Trials) Initiative 
(www.comet-initiative.org) was established to encourage and support the process 
of developing and implementing COS [24]. It was launched in 2010 with the 
following aims: 1) to raise awareness of current problems with outcomes in 
clinical trials, 2) to encourage COS development and uptake, 3) to promote 
patient and public involvement in COS development, 4) to provide resources to 
facilitate these aims, 5) to avoid unnecessary duplication of effort, and 6) to 
encourage evidence-based COS development. 
 
COMET aims to collate and stimulate the development, application and 
promotion of COS, by including data on relevant individual studies in a publically 
available internet-based resource. This database includes publications of previous 
COS development projects, as well as planned and ongoing work. A systematic 
review was undertaken in 2013 that provided a first comprehensive search for 
COS in health research [25]. It identified 198 relevant studies that determined 
which outcomes or domains should be measured in clinical trials for a specific 
health condition. The review revealed wide variation in the methods used to 
develop COS and work is needed to assess the implications of these different 
methods for both minimizing bias and maximizing efficiency in the development 
of COS, and for ensuring uptake. As an example, although benefits have been 
shown for involving patients in trial design, only 16% of the published COS 
reported that there was input from patients in their development [26].  The 
review highlighted the need for methodological guidance, including how to 
engage key stakeholder groups, particularly members of the public, in the 
development and implementation of COS.  
 
This review was updated to the end of 2014, and a further 29 new COS studies 
were identified [27].  There has been a general increase in the number of COS 
over the years, with a consistently higher number of COS published annually in 
recent years than in most years before 2010 (Figure 1). The studies identified 
have been added to the COMET database in order to provide an up-to-date, 
comprehensive database of COS. In addition, to reduce unnecessary duplication 
of effort, ongoing COS studies are also registered in the database. Figure 2 shows 
the number of COS developed, or in development, according to health category. 
Taken together, this work has identified many health areas where a COS has been 
developed and highlighted important gaps.  For example, there has been 
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substantial work on COS for rheumatology and neurology, while mental health 
conditions have not received significant attention. 
 
As awareness of the need for COS continues to grow and knowledge of the 
COMET Initiative increases, asthis is reflected in the website and database usage 
figures [20, 28]. More than 16,500 visits were made to the website in 2014 (36% 
increase over 2013) and 9780 new visitors (43% increase). By December 2014, a 
total of 6588 searches had been completed of the COMET database, with 2383 in 
that year alone (11% increase). An online survey in May-June 2015 was answered 
by 206 (52%) of the 396 visitors to the website, and revealed that the most 
common reasons for searches were ‘I am thinking about developing a core 
outcome set’ and ‘I am planning a clinical trial’.  
 
 
Methods for Developing COS 
 
While standardized methods for the development of COS have not yet been 
widely adopted, a fairly well-defined set of issues to consider are increasingly 
being addressed [19]. A detailed handbook with step-by-step instructions on the 
COS development process has been developed by OMERACT, and is regularly 
updated with insights generated through ongoing COS work [29].  At a high level, 
the first stage in the development of a COS is most frequently a decision on what 
outcomes or outcome domains to measure, followed by agreement on how those 
outcomes should be defined and measured in order to provide the necessary 
data, adopting the outcome specification model previously described [30]. COS 
may include both patient-reported outcomes (PROs) and clinician-reported 
outcomes (ClinROs). Several existing initiatives, described in the next section, are 
relevant to the process of determining how an outcome should be defined and 
measured.; In addition, COMET and COSMIN (COnsensus-based Standards for the 
selection of health Measurement INstruments) have recently collaborated on the 
development of a guideline for instrument selection [31]and a practical guideline 
has recently been developed [29].  
 
As noted above, COS have been developed using a variety of methods [25, 27]. 
These include the use of a literature/systematic review as an early step, which 
rose from 33% (66/198) of the studies in the original review to 72% (21/29) in the 
update. A variety of methods have been used to assess and develop consensus, 
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with the Delphi technique used for 15% (29/198) of the COS in the original review 
and 31% (9/29) in the update. 
The stakeholder groups regarded as key to developing a COS varies between 
health areas. Clinical experts have been involved in all studies, but there has been 
a recent shift towards greater involvement of patient and public representatives. 
This increased, where reported, from 18% (31/174) in the original review, to 59% 
(13/22) in the update, and 89% (66/74) among the ongoing studies that are 
registered in the COMET database.  
 
Involving the public in research can bring challenges and, in response to this need, 
COMET has established the PoPPIE (People and Patient Participation, Involvement 
and Engagement) Working Group to develop resources, including the 
development of plain language summaries in partnership with patients 
(www.comet-initiative.org/resources/PlainLanguageSummary), and pursue a 
research agenda. Research is needed on how to: involve patients as research 
partners in design of COS studies; identify and meet information needs of patients 
as both research partners and participants; identify appropriate methods for 
eliciting consensus among patient groups; generate appropriate questions for 
patients taking part in a COS study; access and engage patients in COS studies; 
ensure hard to reach communities are involved; bring different stakeholder 
groups’ views together; and evaluate the stakeholder experience of taking part.  
 
Other initiatives involving standardized outcomes 
A number of programs and initiatives in the US and elsewhere overlap to some 
degree with the expanding work on COS, and present opportunities for 
coordination and collaboration, as well as the need to avoid duplication of effort.   
 
PROMIS (www.nihpromis.org) is an NIH initiative, implemented through a number 
of leading academic centers, which provides an extensive system of measures of 
patient-reported health status for physical, mental, and social health and can be 
used in studies across a range of medical conditions.  A primary objective of 
PROMIS is to assemble a set of questions to assess the most common dimensions 
of patient–reported outcomes for a wide range of chronic diseases. These include 
items to measure pain, fatigue, psychological distress, physical function, and 
overall health. The PROMIS database of measures focusses on patient-reported 
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outcomes (PROs), while COS generally include both patient-reported and 
clinician-reported outcomes, as well as other outcomes such as laboratory results, 
etc. PROMIS focusses on 'how' to measure 'items' that are patient-reported, 
providing an item question bank. How to measure an outcomeThe 'how' is 
typically the second stage of a COS development process, after determining with 
the 'what' the most important outcomes to measure arecoming first. This two-
stage approach to COS development has the advantage that it can highlight gaps 
in outcome measurement warranting further research, for example the 
identification of an important construct or domain for which no suitable 
measurement instrument currently exists.  In addition, PROMIS does not seek to 
develop agreement around a defined set of minimum outcomes to measure and 
report in a standard fashion across studies, and, by itself therefore, would not 
address the fundamental problems of relevance, consistency or reporting bias 
discussed above. 
The National Institutes of Health (NIH) has is supported a related initiative also 
taken steps to encourage the use of common data elements (CDEs), including 
outcomes, in NIH supported research projects andor registries. The NIH provide a 
resource portal (www.nlm.nih.gov/cde) that includes databases and repositories 
of data elements and case report forms that might help investigators in 
identifying and selecting data elements for use in their projects.  The NIH CDE 
program is most relevant to researchers once they have determined ‘what’ to 
measure, offering resources on ‘how’ to measure both particular outcomes and 
other relevant data items. 
The International Consortium for Health Outcomes Measurement (ICHOM, 
www.ichom.org) organizes global teams of physician leaders, outcomes 
researchers and patient advocates to define core sets of outcomes for use for 
specific health conditions to assess the quality of clinical practice. This initiative 
was established in 2012 with the aim of providing a structured process to achieve 
consensus on health outcomes to be reported for the purpose of comparing the 
performance of competing health care providers.data collected standards to be 
used outside the context of clinical trials, and By the end of 2015, ICHOM had 
completed 12 standard sets, with seven more in progress and the goal of 
completinghopes to publish fifty50 standard sets by 2017. A list of completed 
sets, in progress and conditions under consideration is available at 
www.ichom.org/medical-conditions.  
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ICHOM is focusing on the development of core data sets to evaluate the quality 
and efficiency of clinical care, rather than for use in clinical trials.  The methods 
used by ICHOM differ substantially from those used in the development of COS 
for clinical trials (even taking account of the variability in methods used for the 
latter), as discussed in more detail below.  It is unclear whether the outcomes sets 
developed by ICHOM for clinical care would also be useful for clinical research, 
although there would be value in developing standards that could be used for 
both purposes, making it possible to re-use data collected for either reason.   
As an example, ICHOM recently published their consensus measures for patients 
treated for prostate cancer, pr viding limited detail on the specific methods used 
to reach agreement on the recommended measures. It would be valuable to have 
more information on those methods, such as how the number of patients and 
other stakeholders was decided; how patients were identified, selected and 
involved in the process; how final decisions of the inclusion of an outcome were 
made [32].  In addition, it is important to know how the measuring tools were 
selected. For instance, the ICHOM standards require a record of the date of 
recurrence of an abnormal PSA , but the variety of definitions of PSA recurrence 
(either within a treatment or across treatments) could render comparisons 
difficult and problematic, particularly for clinical trials [33].  
The FDA Clinical Outcome Assessments (COA) Staff aim to encourage the 
development and application of patient-focused endpoint measures in medical 
product development to highlight clinical benefit in labeling. They engage with 
stakeholders to improve clinical outcome measurement standards and policy 
development, by providing guidance on COA development, validation, and 
interpretation of clinical benefit endpoints in clinical trials. Unmet medical needs 
are addressed through the Clinical Outcomes Assessment Qualification Program. 
COA qualification is dependent on appraisal of the evidence to support the 
conclusion that the COA is a well-defined and reliable assessment of a particular 
concept of interest for application in studies used to support drug marketing 
authorization.   The European Medicines Agency (EMA) is working along similar 
lines to increase the use of well validated patient-relevant outcomes in their 
regulatory process.   
The main focus of the FDA and EMA work is understandably on the endpoints to 
be used in product approvals and labelling, and has not been concerned to date 
with the assessment of effectiveness involving outcomes that may be useful for 
non-regulatory decisions by patients, clinicians, payers and others.   From a 
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regulatory perspective, the emphasis is on outcomes that are customized to 
specific products and indications, rather than aiming for greater standardization 
of outcomes across products and studies.  Furthermore, the degree of focus on 
patient-relevant outcomes, and inclusion of patients and the public has been 
limited to date.   This may be changing as a result of greater attention to “patient-
focused drug development”, and may ultimately lead the FDA to greater 
consideration of outcomes that are relevant to and informed by patients [34].  For 
example work on Core Symptom Measures for cancer trials has been promoted in 
prostate, head and neck and ovarian cancers [35]. Whilst the processes to elicit 
expert opinion has included some patient involvement, it is quite limited [33] and 
greater emphasis of wider patient involvement in the process of selecting core 
outcomes is recommended.  
In considering the measurement instruments to use, several may exist for any 
given outcome, usually with varying psychometric properties (i.e. reliability and 
validity). Systematic reviews of measurement instruments provide one way to 
select a measurement instrument for an outcome within a COS. The COSMIN 
(COnsensus-based Standards for the selection of health Measurement 
INstruments) initiative collates systematic reviews of studies of measurement 
properties of existing measurement instruments that intend to measure (aspects 
of) health status or (health-related) quality of life. An overview of these reviews 
and guidelines for performing such reviews can be found at 
www.cosmin.nl/systematic-reviews-of-measurement-properties-_5_0.html.  
However the quality of these reviews varies widely, and there is a lack of reviews 
of outcome measurement instruments for many outcomes in many disease areas 
[36] [ ]. More high quality reviews are needed and the methodology of performing 
such reviews needs to be further developed and implemented. 
Key challenges and moving forward 
While it is encouraging that the level of activity around COS has been increasing, 
substantial work remains to be done, and there are a number of key challenges 
that must be addressed to accelerate progress.   To inform how best to move 
forward, the Center for Medical Technology Policy and the COMET initiative 
hosted a one day COS workshop in April 2014, supported with funding from 
PCORI, The European Union and the UK Medical Research Council.   The meeting 
opened with presentations by ten North American experts currently developing 
COS for use in clinical trials, patient-centered outcomes research (PCOR), 
systematic reviews, quality improvement and other contexts.  Each presentation 
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was followed by discussion and feedback from representatives of federal agencies 
and national organizations with an interest in condition-specific, standardized 
health outcomes, including most of those described above.  The discussions 
underscored the need to expand capacity to develop high quality COS, and 
identified several issues requiring attention to promote further progress.   These 
challenges and potential strategies to address them are summarized below.  
 
Better understanding of the gaps in COS 
The number and quality of COS remains limited, despite the recent increase in 
activity in this field.   While a systematic review of gaps has not yet been done, an 
initial attempt has been made to map the content of the COS database to the 
most prevalent acute and chronic conditions.   For example, no COS have been 
published regarding trials of drug therapy for type 2 diabetes or interventions for 
the management of chronic wounds.   And for many other conditions, the 
available COS have used informal consensus methods rather than structured 
approaches, which might undermine their acceptability for a wide range of 
decision makers.  An initial informal review of conditions identified by the WHO as 
being responsible for the highest global burden of disease [37] has identified key 
gaps. A more systematic assessment of these gaps is now underway.  Again, even 
if existing COS have been identified, further work is needed to determine whether 
they are of adequate quality to broadly promote them broadly. 
An important next step would be to conduct a systematic assessment to identify 
those high prevalence, high burden conditions for which high quality COS do not 
yet exist.  This could be done by using work that has already been done to identify 
and rank burden of illness globally or nationally.   For example, in the US, the 
Agency for Health Ccare Research and Quality (AHRQ) has developed priorities for 
comparative effectiveness research, as have the Institute of Medicine and PCORI.   
Having identified the priority conditions, published COS in those clinical domains 
could be found relatively simply through the COMET database.  Finally, these COS 
would be need to be assessed for quality, of both their methods and reporting.   
As noted below, work is underway to develop quality assessment and reporting 
tools for COS, but the initial quality screening could look for a few basic indicators 
of quality, such as the inclusion of patients or consumers in the development 
process.  
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Expanded capacity to produce COS 
As priority areas for COS are identified, mechanisms need to be in place to 
support their development and implementation. This will require research to 
identify best practices for COS development and the production of a reporting 
guideline to facilitate clear reporting of the COS and the processes used to 
develop it (see below). This would likely be accelerated by an increased interest in 
research funding agencies to support the development of high priority COS, and 
of the methods and tools necessary to support groups involved in this work.   The 
nature of this work requires multi-stakeholder collaboration, ideally at the 
national or international level.  Ideally, many of these initiatives would include 
leadership from the patient advocacy organizations relevant to each topic.  In this 
way, the benefits of COS for reducing waste in research will not arise from 
wasteful practices in their development [38] . 
As part of its effort to support COS developers, the COMET database includes 
previous work that might help the development of new COS, alongside the 
reports of COS themselves. For example, an initial step in COS development is 
usually a review of outcomes measured in previous clinical trials and work to 
identify outcomes felt to be important by patients. With this in mind, the 
database includes more than 120 reviews of outcomes measured in trials and 52 
studies of patients’ perspectives on outcomes to be measured in their condition. 
 
Improving the quality of COS 
The afore-mentioned systematic review and its update revealed wide variation in 
the methods used to develop COS, with no clear consensus on best practice ([25]; 
Gorst et al, in preparation). Although key issues to consider when developing a 
COS have been described [19], there is little or no guidance on how to choose and 
involve stakeholders, develop consensus, achieve geographical representation, or 
undertake many other aspects of the process.     
One of the urgent areas of need is to expand engagement of patients and the 
public in the development of COS.   As noted above, a significant minority of 
publicationsshed reported any patient or public involvement in the process.  
There is anecdotal evidence to suggest that this has started to shift, and the 
forthcoming updated systematic review of COS will provide more recent empirical 
data.  Given the rapidly increasing recognition of the need to develop, validate 
and report outcomes that are meaningful to patients, it is a critical priority to fund 
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methods research to develop and validate formal qualitative methods to 
effectively engage patients and the public in this process.    The absence of 
empirically-based best practices should not prevent the development of initial 
consensus around key principles and techniques.   Once documented and 
standardized to some extent, it will be possible to do empirical work to evaluate 
the effectiveness of alternative approaches.  
When best practices have been developed, it will also be possible and useful to 
develop a quality assessment tool.  Although nearly 230 published COS studies 
have already been identified, the lack of an assessment tool means that there has 
been no formal quality assessment of these. Defining the quality of a COS is not 
straightforward. Ultimately, a “good” COS would be one that leads to improved 
health outcomes but this might be far down-stream of the development process 
and difficult to measure. It is also unlikely to be a feature of any report describing 
the development of a COS. Instead, a tool is needed to assess how the COS 
developers minimized biases which would otherwise undermine the ability of the 
COS to have a positive impact on patient care and outcomes. This would be 
analogous to the Cochrane Risk of Bias tool for assessing the studies to include in 
systematic reviews [39]. 
Along with best practice guidance and metrics to assess the quality of COS, it will 
be valuable to develop a standardized reporting tool for publications and reports 
of COS.  Although a preliminary checklist was proposed for the reporting of Delphi 
surveys used in the development of COS [40], this is not sufficient to address the 
wider aspects of COS studies. COS studies are still not well reported in terms of 
the scope and methods used in their development of the COS. Information that 
might help users to decide whether to adopt a COS or develop a new one is often 
lacking. To try to redress this, work is underway to develop a COS reporting 
guideline, using an international consensus process [41]. The initial areas under 
consideration include the rationale for and scope of the COS, methods of 
development, stakeholder involvement, sources of information, consensus 
process, limitations, and plans for implementation and updating.  
 
Increasing uptake of high quality COS 
Where high quality COS exist or are developed, they will need to be widely 
accepted and implemented by the majority of researchers if their benefits for 
health are to be realized.   Publication and broad dissemination of the COS is a 
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basic requirement, and the simplified access to relevant reports and papers is 
now possible as a result of the work of COMET’s work.  Stronger incentives are 
likely to be necessary for high levels of uptake;, for example, the recognition or 
endorsement of COS by research funding organizations, journal editors, clinical 
guideline developers and payer/HTA organizations.   Researchers should be 
considerably more likely to give serious consideration to COS when that decision 
has the potential to impact the funding of their research, publication of their 
results, of have an influence over clinical policy or reimbursement.   
With respect to research funders, the National Institute for Health Research 
(NIHR) in the UK provides the f llowing text in their guidance notes for applicants: 
“Where established Core Outcomes exist they should be included amongst the list 
of outcomes unless there is good reason to do otherwise. Please see The COMET 
Initiative website at www.comet-initiative.org to identify whether Core Outcomes 
have been established”.  There are not yet examples of US funders making explicit 
reference to COS, but the NIH, AHRQ, PCORI and others may wish to consider 
under what circumstances it would be reasonable to do so.  
Some journal editors have begun to encourage consideration of COS by 
researchers.  The SPIRIT guidance for reporting protocols of clinical trials [42] 
recommends “Where possible, the development and adoption of a common set 
of key trial outcomes within a specialty can help to deter selective reporting of 
outcomes and to facilitate comparisons and pooling of results across trials in a 
meta-analysis. The COMET (Core Outcome Measures in Effectiveness Trials) 
Initiative aims to facilitate the development and application of such standardized 
sets of core outcomes for clinical trials of specific conditions (www.comet-
initiative.org). Trial investigators are encouragesd investigators to ascertain 
whether there is a core outcome set relevant to their trial and, if so, to include 
those outcomes in their trial. Existence of a common set of outcomes does not 
preclude inclusion of additional relevant outcomes for a given trial”. Finally, in 
obstetrics and gynecology, the CROWN (Core Outcomes in Women’s Health) 
Initiative (www.crowninitiative.org) is a consortium of more than 70 journal 
editors that will “strongly encourage the reporting of results for core outcome 
sets. Facilitate embedding of core outcome sets in research practice, working 
closely with researchers, reviewers, funders and guideline makers”. 
There is considerable potential for increasing uptake of COS through the 
mechanism of recognition by clinical guideline developers, HTA organizations and 
payers – as these groups all carry substantial influence through their direct 
Page 38 of 54
https://mc04.manuscriptcentral.com/fm-cer
Journal of Comparative Effectiveness Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
Tunis et al., page 18 
 
influence on the evidence-based reimbursement of products and services.  The 
manual for guideline development by the National Institute for Health and Care 
Excellence (NICE) recommends the COMET database as a source of information to 
be considered (NICE, 2012).   The Green Park Collaborative (GPC) in the US 
(www.cmtpnet.org/featured-projects/green-park-collaborative) develops 
recommendations for research in specific therapeutic areas, through a multi-
stakeholder collaborative process that includes payers, guideline developers, HTA 
organizations, as well as patients, clinicians and other key stakeholders.   A 
number of GPC projects have attempted to increase the measurement and 
reporting of patient-relevant outcomes [43].  Efforts are also underway to 
leverage the broad range of decision making authority represented by the 
membership of this collaborative to promote the uptake of high quality COS.    
Ultimately, it is likely that explicit recognition or formal endorsement of COS will 
be necessary to ensure the level of consistent use that will achieve the original 
objectives of this work. 
 
Conclusions 
If comparative effectiveness research is to have an impact on practice and, 
thereby, the health of patients and the public, it needs to ensure that the 
outcomes that matter most to the people making decisions and choices are 
developed, measured and reported. Core outcome sets can facilitate this, 
especially when their development and implementation is integrated with other 
key initiatives to improve research and practice. There are several challenges to 
overcome. Work is already underway to meet some of these, including a database 
of all identified COS, research to identify best practices and the development of a 
reporting guideline. However, much remains to be done. Health areas in 
particular need of COS have to be identified, the development of high quality COS 
to meet this need has to be encouraged and supported, and these COS have to be 
implemented in research and practice. 
In addition to standardized outcomes in clinical trials, consistent reporting of 
outcomes is also important for studies of the onset, course and consequences of 
disease. To this end, clinical cohorts, registries and observational databases have 
been established; and routinely collected data from within electronic medical 
record (EMR) systems is likely to become increasingly available in the future to 
support research. The EMR provides real-world clinical information and is a 
sustainable source of data. The overlap between data from research databases 
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and from EMR systems for clinical care could be valuable. Therefore, tTo achieve 
the full potential of such an approach, it is vital that similar attention is paid to the 
choice and definition of outcomes that should be collected within such systems.  
It has also been proposed that prospective registries of clinical trials should place 
increased emphasis on COS [44]. For example, registries could encourage 
researchers to note their use of a COS when they register their trial, perhaps with 
a prompt for them to consider using a COS and a simple way for them to specific 
the outcomes by a link through to the original COS.   
There are several serious challenges to overcome. Some useful work is already 
underway as discussed in this paper. However, much remains to be done, and the 
effort will need to be focused, coherent and sustained. Health areas in particular 
need of COS have to be identified, the development of high quality COS to meet 
this need has to be encouraged and supported, and these COS have to be 
implemented in research and practice.  Ultimately, the failure to consistently 
develop, measure and report the outcomes most meaningful to patients in 
research is both wasteful and harmful, to research participants and to patients.  
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Figure 1 Year of first publication of each COS study (n=227) 
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Figure 2 Number of COS developed in each disease category (n=305)  
 
*Studies we are aware have been published since December 2014 
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Peer reviewer comments 
 
Please include all responses in this document starting each response with ‘Author response’. 
We recommend marking changes made in response to different peer reviewers’ comments in 
different colors in the revised text of your manuscript. 
 
Peer reviewer 1 comments 
 
1. Overall: This seems an extremely comprehensive paper on Core Outcome Measures (COMs) and 
I appreciate the authors' expertise and breadth of knowledge. I presume this knowledge and 
interest stems from a strongly held belief that these measures are very important and need to 
be encouraged to be used more widely, and also need validating studies. 
 
However, this passion doesn't come across strongly enough in the language. Given this is a 
perspective, and the authors are allowed to be opinionated, I would truly like to see more 
vigorous defense of the ideas presented. Be subjective--this is one of the few opportunities you 
are allowed in academic publishing to state your case; I encourage you to do it with more 
intensity. 
Author response: 
 
We strengthened the language in the introduction to make more obvious our belief in the 
significance of the problem and the need for sustained action. 
 
Please note that we also changed the title of the paper, to now address “comparative effectiveness 
research” rather than limited to “clinical trials”.   We wanted to emphasize that the value of COS 
extends to all types of prospective CER, not just clinical trials. 
 
Specifics: 
 
1. Abstract: I rewrote your abstract to bring out the main point more clearly and forcefully: Policy 
makers have clearly indicated--through heavy investment in the Patient Centered Outcomes 
Research Institute (PCORI)--that reporting outcomes which are meaningful to patients is crucial 
for improvement in health care delivery and cost reduction. Better interpretation and 
generalizability of clinical research results that incorporate PCOR can be achieved by accelerating 
the development and uptake of Core Outcome Sets (COS). 
 
NOTE: I've also attached the PDF wherein these comments/edits are also made. 
Author response: 
 
Thanks very much for taking the time to revise the abstract.    We agree that this new version makes 
the main points more clearly and forcefully.   We merged the suggested new language and modified 
the original language to create a new abstract. 
 
2. Page 2, Line 5: 'Describe' s/b 'describing' 
Author response: 
 
Change made 
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3. Page 2, Lines 42-51: Sentences beginning with "Medicare... and ending with ...'quality of life". 
There should be references for this information 
 
Author response: 
 
A citation has been added for each example. 
 
4. Page 3, Line 24: Sentence beginning "For example..." Powerful and clear statement of the 
problem 
Author response: 
 
Agree that this example captures the problem effectively. 
 
5. Page 5, Line 24: Re; measurement: Many PI's of clinical research don't understand why this 
would be a problem; even some statisticians don't always catch that this is an issue. We don't 
have many measurement-savvy folks in research, ironically. 
Author response: 
 
This comment does not appear to require any changes. 
 
6. Page 7, Line 52: "As awareness" can become "Awareness", and 'increases, this is reflected' can 
become 'increases as reflected' 
Author response: 
 
Suggested changes made 
 
7. Page 9, Line 46: Why are 'how', 'what', and 'items' in quotes? And a general comment on this 
statement is that I agree that PROMIS would not address these issues, but I would also argue 
that 'how' and 'what' are often conjoined questions: some 'whats' are negated by the difficulty 
of their measurement, by their 'hows'. 
Author response: 
 
Text was added to respond to this comment, removing the quotes around the terms, and using 
simpler language to explain the relevant concepts.  We hope that this helps to clarify the distinction 
between which outcomes to measure and how to measure them. 
 
8. Page 10, Line 4: You've already introduced the acronym NIH. 
Author response: 
 
We have now inserted the acronym 
 
9. Page 10, paragraph beginning with Line 4: It's possible this paragraph would be better as the 
introductory paragraph to NIH initiatives (and perhaps, given how it's written, it once was?). You 
might consider switching it with the paragraph on PROMIS above. 
Author response: 
 
We have reviewed this section and believe that the current order of the paragraphs works best.   We 
altered some of the language in the first line of this paragraph in order to clarify that the CDE 
program is a second NIH initiative (in addition to PROMIS). 
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10. Page 10, Line 20: Sentence beginning "This initiative was established with the aim of providing a 
structured process to achieve consensus data collected standards to be used outside the context 
of clinical trials" Something doesn't read right here. Do you want to use "Collecting"? 
"Collection"? Is there a comma missing? 
Author response: 
 
Agree that the language was awkward, and these sentences have been reworded. 
 
11. Page 11, first two paragraphs on FDA and EMA: I understand why it's here, but it seems a bit of a 
tangent, and the article could use some trimming. This may be a spot to do it. 
Author response: 
 
We believe that the FDA work is important to mention because future efforts to increase work on 
COS will need to be aligned with related FDA activities.   We have removed several sentences with 
information that we considered to be less essential. 
 
12. Page 12, Line 58: 'to broadly promote' would read better 'to promote them broadly'. 
Author response: 
 
Change made 
 
13. Page 14, Line 18: Should 'published' be 'publications'? 
Author response: 
 
Change made 
 
14. Page 14, Line 24: Strike "methods" at the end of the line 
Author response: 
 
Change made 
 
15. Page 15, Line 5: Should read '...the scope and methods used in their development." 
Author response: 
 
Change made 
 
16. Page 15, Line 26: Should read '...now possible as a result of COMET's work" 
Author response: 
 
Change made 
 
17. Page 15, Line 28: Should replace comma with semi-colon: '...be necessary for high levels of 
uptake; for example'... 
Author response: 
 
Change made 
 
18. Page 15, Line 50: I would take out the quote by SPIRIT, since it is essentially redundant to the 
quote in the previous paragraph, and so have the paragraph read: "Some journal editors have 
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begun to encourage consideration of COS by researchers. The SPIRIT guidance for reporting 
protocols of clinical trials [39] encourages trial investigators to ascertain...." 
Author response: 
This suggested edit has been made. 
 
Peer reviewer 2 comments  
 
The article provides a nice overview of current problems in outcome measurement and initiatives in 
the field of Core Outcome Set development. I have a few suggestions for consideration. 
 
1. Page 2, description of current problems with the outcomes in clinical trials: I suggest to add two 
additional problems. I think that 5 problems could be mentioned here; (1) variation in outcomes 
being measured; (2) Lack of measured outcomes that are relevant for patients; (3) Biased 
reporting of outcomes; (4) Variation in outcome measurement instruments used; and (5) lack of 
information on the measurement properties of the measurement instruments. The latter two 
issues could perhaps be added to this discussion. 
Author response: 
 
This is a helpful comment, and we have added these additional problems in the section on “current 
problems”, and added text to describe these problems in more detail below. 
 
2. Page 3, paragraph on second major problem: in this paragraph actually three problems are being 
mentioned: variability in outcomes being measured, variability in outcomes being reported (and 
outcome reporting bias) and variability in measurement instruments being used. These different 
problems could be better distinguished in the paper. 
Author response: 
 
Text has been added in a paragraph following the previous description of the second major problem, 
reflecting the thoughts provided in this comment. 
 
3. It would be interesting to include a bit more literature on problems with outcomes in meta-
analysis. For example, the paper by Furukawa found that approximately half of the RCTs do not 
contribute to the pooled effect size in meta-analyses due to differences in outcome measures 
(Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between 
unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007 Feb 
7;297(5):468-70.) 
Author response: 
 
We provided additional text and a reference related to this issue at the end of the paragraph on the 
fifth problem with COS (which would appear after page 4, line 31 in the PDF version of the original 
submission). 
 
4. Page 8, methods for developing COS: In this paragraph more emphasis could be placed on the 
distinction between WHAT to measure and HOW to measure. Also, it would be nice to mention 
the collaboration between COMET and COSMIN on the development of the guideline for 
instrument selection (reference 28). In addition, a reference to the protocol of this study could 
me added: Prinsen CAC, Vohra S, Rose MR, King-Jones S, Ishaque S, Bhaloo Z, Adams D, Terwee 
CB. Core Outcome Measures in Effectiveness Trials (COMET) Initiative: Protocol for an 
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international Delphi study to achieve consensus on how to select outcome measurement 
instruments for outcomes included in a 'Core Outcome Set'. Trials 2014;15:247. 
Author response: 
 
The COMET-COSMIN collaboration is now mentioned, along with this reference, in the section on 
methods for COS development. 
 
5. Page 9, PROMIS: I have two suggestions for this paragraph: First, I suggest to not only mention 
the NIH as the founder of PROMIS, but also mention the initial 6 US research centers (especially 
Northwestern University) to acknowledge their incredible efforts. Second, I think the unique 
features of PROMIS (e.g. improved content, possibility for Computer Adaptive Testing) could be 
more fully addressed. The focus in this paragraph is now a bit too much on what they do not do 
and perhaps a bit too little on what they offer for the field of outcome measurement. 
Author response: 
 
We fully recognize the effort required and importance of PROMIS, and have added some text to the 
first sentence of the description to reflect the spirit of this comment.   However we don’t feel that 
adding this level of detail about each of the initiatives mentioned would be within the scope of the 
paper.   Our purpose is to mainly identify the most developed initiatives in the COS space, and 
describe what they do and don’t do at a very high level, as general context for making the point that 
a lot of white space remains, and that efforts to coordinate and fill gaps is key.   In addition, we are 
already looking for ways to shorten the manuscript, so would not be able to expand this section of 
the paper in the direction suggested. 
 
6. Page 12 and onward, challenges and moving forward: I recommend to mention somewhere the 
need for more high quality systematic reviews of outcome measurement instruments. These 
systematic reviews are a very important tool for instrument selection for COS and are a key 
element in the guideline for selecting outcome measurement instruments for COS [ref 28]. 
However, there are a number of problems that are worth mentioning: there is a lack of 
systematic reviews of outcome measurement instruments for many outcomes in many disease 
areas. COS developers can help to fill this gap. Furthermore, the quality of these reviews vary 
widely (Terwee CB, Prinsen CAC, Ricci Garotti MG, Suman A, de Vet HCW, Mokkink LB. The 
quality of systematic reviews of health-related outcome measurement instruments. Qual Life 
Res 2015 Aug 29 [Epub ahead of print]). More high quality reviews are needed and the 
methodology of performing such reviews needs to be further developed and implemented. 
Author response: 
 
We have added a brief paragraph reflecting these points and including the suggested reference at 
the top of page 14 of the revised manuscript, just before the section on key challenges.   We believe 
that there is a need for a full paper on this important topic, but that adding more detail in this paper 
would potentially distract from the primary messages and focus. 
 
Peer reviewer 3 comments 
 
It is an interesting topic and has a lot of helpful cites to existing (international) initiatives, but it's way 
too hard to read. 
 
1. This MS was hard to navigate because the structure was not clear and the "order" of some of the 
examples wasn't obvious (it wasn't chronological). It was much too verbose, many paragraphs 
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and sentences simply too complicated to follow (or didn't belong together because long 
paragraphs wandered far afield of the topic sentence); a fair number of mistaken usage of basic 
English terms. 
Author response: 
We went through the entire manuscript and made changes were possible to clarify, simplify and 
correct grammar and terminology that we were able to identify as problematic 
 
2. Content 
a. Use of COS as a plural was confusing -- suggest when is intended to be plural, use COSs 
and define COS as relating to a set, not sets. 
Author response: 
 
We use the term COS studies where the plural was required. 
 
b. Public health on p. 1: I think this is a mistake -- surely the authors mean health of the 
public, which isn't the same thing. 
Author response: 
 
Changed “public health” to “health outcomes” 
 
c. p. 4: so what if final publications don't exactly track protocols, when for some kinds of 
research (or systematic reviews), one can amend (i.e., not revise) them to show what 
finally got done and what the explanation is for the differences. 
Author response: 
 
We added a clarifying sentence after the current text on page 4, lines 24-31 to further explain why 
this high frequency of changes to the primary outcome of a study between the protocol and 
published studies is widely viewed to be problematic. 
 
d. The authors mention the National Quality Forum, but I do not think fully or entirely 
correctly. NQF endorses measures (or measure sets); it does not develop them. What's 
more, NQF has a substantial program or initiative in using PROs (or PRO measures, aka 
PROMs), and none of that is mentioned. Consequently, this seems either old info or just 
incomplete info, and I don't think that's sensible (for a US audience anyhow). When later 
(p. 10) they mention quality of clinical practice (aka patient care), they do not return to 
NQF but mention only ICHOM) -- one example of what seemed to me to be a "bias" 
toward international programs (in which US folks may well participate) but not so just 
that's up to date on US programs.... I suppose whether that's a problem or not is for the 
journal to decide. (BTW: AHRQ's name is incorrectly stated in p. 13.) 
Author response: 
 
In the paragraph mentioning NQF (page 5, lines 12-23) we changed “developed” to “endorsed” and 
mentioned that the NQF measures include patient reported outcomes.   It would be possible to add 
more detail about the NQF in the section on other initiatives, but for the sake of space, chose not to 
do so.  We also used the correct name for AHRQ (which uses “healthcare” as one word). 
 
 
e. p. 7-8: wondered whether some of this COMET stuff could be updated to "today." 
 
Author response: 
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The COMET database statistics are updated annually, so those included in the paper are the most 
recent available.    
 
f. The descriptions of PROMIS are, in my opinion, not quite accurate, and the implied 
criticism about what can be done with PROMIS (through its Assessment Center, which 
probably should have been given its own URL) seemed off base to me -- PROMIS permits 
CATs (and "kitties" for that matter for peds), but it also lets people create their own 
"traditional" short forms. I think the conceptual framework for PROMIS is also more 
sophisticated than seems to be described here.  
 
Somewhere in all this, the authors might want to look into a new book from the RTI 
Press: first author is Dave Cella and others are all senior researchers at Northwestern U 
and nationally or internationally known experts in outcomes measurement/research. 
Author response: 
 
A number of revisions were made to the section describing PROMIS which we believe address 
comments from both reviewer 1 and reviewer 3.   We are familiar with the excellent book by Dave 
Cella on PROs for use in performance measurement.   This contains detailed material on 
methodological issues in PROs use to measure provider performance, and we did not feel that it was 
necessary to add this reference to the text.  
 
Comments from the Editor 
 
1. Please include a ‘Future Perspective’ section: a concluding paragraph in which authors are 
challenged to include a speculative viewpoint on how the field will evolve over the next 5–10 
years from the point at which the review was written. 
Author response: 
 
We have modified the conclusion section to offer some general perspectives about what needs to be 
done over the next 5 to 10 years.   The paper itself is really devoted to what needs to be done going 
forward, so it is not clear that a separate future perspective section will offer new ideas. 
 
2. Please include an ‘Executive Summary’: bulleted summary points that illustrate the main topics 
or conclusions made under each of the main headings of the article (800 words maximum). 
Author response: 
 
We have a working draft of this executive summary but are not sure that it is required for this type 
of article.   Please let us know if this is needed. 
 
Please find a link to the Future Medicine Author Guidelines which explain these sections in more 
detail: 
 
http://www.futuremedicine.com/page/authors.jsp 
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